Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Hypercalcemia Treatment Market – Insights

Hypercalcemia is characterized by increased level of calcium in the blood. The condition can be life-threatening and is associated with neoplastic diseases. Hypocalcemic drugs are used for the treatment of hypercalcemia.

The global hypercalcemia treatment market is estimated to account for US$ 10,696.6 Mn in terms of value in 2018 and is expected to reach US$ 28,060.0 Mn by the end of 2028.

Global Hypercalcemia Treatment Market: Drivers

High incidence of hypercalcemia is a major factor boosting growth of the global hypercalcemia treatment market. For instance, in the study, ‘Incidence of hypocalcemia and hypercalcemia in hospitalized patients: Is it changing?’, published in the Journal of Clinical and Translational Endocrinology, in September 2018, researchers found that 27.72% of the study patients suffered from hypocalcemia and 4.74% from hypercalcemia. Moreover, 585 cases of hypercalcemia were detected.

Moreover, increasing prevalence of cancer is also expected to aid in growth of the market. For instance, according to the World Health Organization, around 18.1 million new cases and 9.6 million deaths were registered due to cancer worldwide in 2018.

Moreover, favorable reimbursement scenario is also expected to aid in growth of the market. Reimbursements enable lesser out-of-pocket costs of treatment for patients, despite having a low income eligibility. For instance, Amgen has a reimbursement policy on its XGEVA (denosumab injection), in which the company pays the out-of-pocket amount in excess of US$ 25 per dose; up to US$ 10,000 in assistance per calendar year. Approximately 70% of XGEVA patients with commercial or Medicare coverage incurred US$ 0 out-of-pocket cost due to favorable reimbursement policy offered by Amgen, Inc.

North America region held dominant position in the global hypercalcemia treatment market in 2018, accounting for 45.5% share in terms of value, followed by Europe.

Hypercalcemia Treatment  | Coherent Market Insights

Global Hypercalcemia Treatment Market: Restraints

Companies face challenges with regard to locating patients for clinical trials and logistics issues related to institutes conducting trials. Such factors increase the costs incurred in R&D of hypercalcemia treatment, which is expected to hinder growth of the global hypercalcemia treatment market.

Moreover, it is challenging to distinguishing primary hyperparathyroidism from conditions that will not respond to parathyroidectomy, which is also expected to limit growth of the market.

Global Hypercalcemia Treatment Market: Opportunities

Product innovations in hypercalcemia drug types other than bisphosphonates is expected to offer lucrative growth opportunities for players in the global hypercalcemia treatment market. Bisphosphonate is the single largest product being utilized for hypercalcemia treatment. End users have recognized the bisphosphonate therapy as effective. Still, the global hypercalcemia treatment market is yet to witness major product innovations in the product types of calcitonin, calcimimetics, and glucocorticoids.

Improving systems for recognizing hypercalcemia can aid in addressing common causes for delayed diagnosis and treatment of the disease, thereby aiding in growth of the market. Educating patients and providers about the consequences of untreated disease can also help in this regard.

Hypercalcemia Treatment  | Coherent Market Insights

Bisphosphonates segment in the global hypercalcemia treatment market was valued at US$ 7,306.2 Mn in 2018 and is expected to reach US$ 19,798.3 Mn by 2027 at a CAGR of 11.7% during the forecast period.

Market Trends/Key Takeaways

R&D in the treatment of hypercalcemia is augmenting growth of the market. For instance, in July 2019, researchers from Ascendis Pharma A/S, in their study, ‘Design and Preclinical Development of TransCon PTH, an Investigational Sustained?Release PTH Replacement Therapy for Hypoparathyroidism,’ reported that TransCon PTH can be used to normalize blood levels of calcium and phosphate.

Sarcoidosis, a complex disease with no known cause, is linked with hypercalcemia. The study, “Hypercalcemic pancreatitis a rare presentation of sarcoidosis: A case report,” published in the journal Medicine in January 2018, reported a sarcoidosis patient with pancreatitis — inflammation of the pancreas — and hypercalcemia.

Hypercalcemia Treatment  | Coherent Market Insights

Global Hypercalcemia Treatment Market: Competitive Landscape

Major players operating in the global hypercalcemia treatment market include, Bayer Pharma AG, Sun Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Amgen Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Cipla Inc., and XOMA Corporation.

Global Hypercalcemia Treatment Market: Key Developments 

Players in the market are focused on attending various conferences to expand their customer base. For instance, in October 2019, XOMA Corporation presented at the 2019 Cantor Fitzgerald Global Healthcare Conference held in New York.

Hypercalcemia is increased level of calcium in the blood which is caused majorly due to malignancy or hyperparathyroidism. Approximately 20 to 30% of cancer patients suffer from hypercalcemia. Hypercalcemia due to cancer is of four types such as humoral hypercalcemia of malignancy, osteolytic hypercalcemia, secretion of active vitamin D by some lymphomas, and ectopic parathyroid hormone (PTH) secretion which is a rare type. Treatment options of hypercalcemia include bisphosphonates, calcitonin, glucocorticoids, denosumab, and calcimimetics. Bisphosphonates are highly prescribed medicines for management of hypercalcemia.

Restraints of the Global Hypercalcemia Treatment Market

Factors such as low research and development due to clinical trials issues (difficulty in finding patients), and limited treatment options are expected to hinder growth of the market over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the global hypercalcemia treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global hypercalcemia treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Bayer Pharma AG, Sun Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Amgen Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Cipla Inc., and XOMA Corporation.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global hypercalcemia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  •  Global Hypercalcemia Treatment Market, By Drug Type:
    • Bisphosphonates
      • Clodronate
      • Etidronate
      • Ibandronate
      • Pamidronate
      • Zoledronic Acid
    • Calcitonin
    • Glucocorticoids
    • Denosumab
    • Calcimimetics
  • Global Hypercalcemia Treatment Market, By Distribution Channel:
    • Hospitals
    • Clinics
    • Independent Pharmacy & Drug Stores
  • Global Hypercalcemia Treatment Market, By Geography:
    • North America
      • By Drug Type
        • Bisphosphonates
          • Clodronate
          • Etidronate
          • Ibandronate
          • Pamidronate
          • Zoledronic Acid
        • Calcitonin
        • Glucocorticoids
        • Denosumab
        • Calcimimetics
      • By Distribution Channel
        • Hospitals
        • Clinics
        • Independent Pharmacy & Drug Stores
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Drug Type
        • Bisphosphonates
          • Clodronate
          • Etidronate
          • Ibandronate
          • Pamidronate
          • Zoledronic Acid
        • Calcitonin
        • Glucocorticoids
        • Denosumab
        • Calcimimetics
      • By Distribution Channel
        • Hospitals
        • Clinics
        • Independent Pharmacy & Drug Stores
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type
        • Bisphosphonates
          • Clodronate
          • Etidronate
          • Ibandronate
          • Pamidronate
          • Zoledronic Acid
        • Calcitonin
        • Glucocorticoids
        • Denosumab
        • Calcimimetics
      • By Distribution Channel
        • Hospitals
        • Clinics
        • Independent Pharmacy & Drug Stores
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Drug Type
        • Bisphosphonates
          • Clodronate
          • Etidronate
          • Ibandronate
          • Pamidronate
          • Zoledronic Acid
        • Calcitonin
        • Glucocorticoids
        • Denosumab
        • Calcimimetics
      • By Distribution Channel
        • Hospitals
        • Clinics
        • Independent Pharmacy & Drug Stores
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East:
      • By Drug Type
        • Bisphosphonates
          • Clodronate
          • Etidronate
          • Ibandronate
          • Pamidronate
          • Zoledronic Acid
        • Calcitonin
        • Glucocorticoids
        • Denosumab
        • Calcimimetics
      • By Distribution Channel
        • Hospitals
        • Clinics
        • Independent Pharmacy & Drug Stores
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type
        • Bisphosphonates
          • Clodronate
          • Etidronate
          • Ibandronate
          • Pamidronate
          • Zoledronic Acid
        • Calcitonin
        • Glucocorticoids
        • Denosumab
        • Calcimimetics
      • By Distribution Channel
        • Hospitals
        • Clinics
        • Independent Pharmacy & Drug Stores
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Bayer Pharma AG*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Sun Pharmaceutical Industries Ltd.
    • Mylan N.V.
    • Pfizer Inc.
    • Amgen Inc.
    • Novartis AG
    • Dr. Reddy’s Laboratories Ltd.
    • Cipla Inc.
    • XOMA Corporation

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug
      • Market Snippet, By Distribution Channel
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • Reimbursement Scenario
    • Pipeline Analysis
  4. Global Hypercalcemia Treatment Market, By Drug, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Bisphosphonates
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
        • Clodronate
        • Etidronate
        • Ibandronate
        • Pamidronate
        • Zoledronic Acid
    • Calcitonin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Glucocorticoids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Denosumab
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Calcimimetics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
  5. Global Hypercalcemia Treatment Market, By Distribution Channel, 2016 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Independent Pharmacy & Drug Stores
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Hypercalcemia Treatment Market, By Regions, 2016 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  7. Competitive Landscape
    • Company Profiles
      • Bayer Pharma AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sun Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Mylan N.V.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Amgen Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Dr. Reddy’s Laboratories Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Cipla Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • XOMA Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 33 market data tables and 22 figures on “Hypercalcemia Treatment Market – Global forecast to 2027.

Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner